Abstract
Limited treatment options have been available for people with HIV who have had virological failure of the three original classes of HIV antiretroviral drugs-so-called triple-class virological failure (TCVF). However, introduction of new drugs and drug classes might have improved outcomes. We aimed to assess trends in virological and clinical outcomes for individuals with TCVF in 2000-09.
Lingua originale | English |
---|---|
pagine (da-a) | 119-127 |
Numero di pagine | 9 |
Rivista | The Lancet Infectious Diseases |
Volume | 12 |
DOI | |
Stato di pubblicazione | Pubblicato - 2012 |
Keywords
- Adolescent
- Adult
- Anti-HIV Agents
- CD4 Lymphocyte Count
- Cohort Studies
- Female
- HIV Infections
- HIV-1
- Humans
- Male
- Middle Aged
- RNA, Viral
- Regression Analysis
- Retrospective Studies
- Young Adult